Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?

BACKGROUND: Standard treatment of colorectal cancer includes both cytostatic chemotherapy and targeted therapies. Bevacizumab, targeting the VEGF receptor, is one of the primary targeted therapies that achieve better response rate and survival rate as compared to combination chemotherapy. To the bes...

Descripción completa

Detalles Bibliográficos
Autores principales: Sümbül, Ahmet Taner, Dişel, Umut, Sezgin, Nurzen, Sezer, Ahmet, Köse, Fatih, Beşen, Ali Ayberk, Sümbül, Zehra, Abalı, Hüseyin, Özyılkan, Özgür
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2014
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962326/
https://www.ncbi.nlm.nih.gov/pubmed/24632679
http://dx.doi.org/10.12659/MSM.889945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962326/
https://www.ncbi.nlm.nih.gov/pubmed/24632679
http://dx.doi.org/10.12659/MSM.889945

Ejemplares similares